[{"address1": "80 Guest Street", "address2": "5th Floor", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8864", "website": "https://www.aurabiosciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette\u0096gu\u00e9rin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 88, "companyOfficers": [{"maxAge": 1, "name": "Dr. Elisabet  de los Pinos Ph.D.", "age": 49, "title": "Founder, CEO, President & Director", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 895160, "exercisedValue": 0, "unexercisedValue": 4928582}, {"maxAge": 1, "name": "Ms. Julie B. Feder", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 604199, "exercisedValue": 0, "unexercisedValue": 1048670}, {"maxAge": 1, "name": "Dr. Mark  Plavsic D.V.M., Ph.D.", "age": 62, "title": "Chief Technology Officer", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Conor  Kilroy", "age": 41, "title": "General Counsel & Secretary", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  Nealon", "title": "Senior Vice President of Clinical Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.69, "open": 7.78, "dayLow": 7.7, "dayHigh": 8.09, "regularMarketPreviousClose": 7.69, "regularMarketOpen": 7.78, "regularMarketDayLow": 7.7, "regularMarketDayHigh": 8.09, "beta": 0.35, "forwardPE": -4.0102563, "volume": 83440, "regularMarketVolume": 83440, "averageVolume": 178693, "averageVolume10days": 90430, "averageDailyVolume10Day": 90430, "bid": 7.81, "ask": 7.88, "bidSize": 100, "askSize": 200, "marketCap": 387919712, "fiftyTwoWeekLow": 5.99, "fiftyTwoWeekHigh": 12.35, "fiftyDayAverage": 8.2763, "twoHundredDayAverage": 8.028225, "currency": "USD", "enterpriseValue": 213089024, "floatShares": 34176629, "sharesOutstanding": 49606100, "sharesShort": 1228430, "sharesShortPriorMonth": 3311101, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0248, "heldPercentInsiders": 0.07524, "heldPercentInstitutions": 0.80117, "shortRatio": 6.46, "shortPercentOfFloat": 0.0336, "impliedSharesOutstanding": 49606100, "bookValue": 3.861, "priceToBook": 2.025382, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -80686000, "trailingEps": -1.79, "forwardEps": -1.95, "enterpriseToEbitda": -2.393, "52WeekChange": -0.2145046, "SandP52WeekChange": 0.24014747, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "AURA", "underlyingSymbol": "AURA", "shortName": "Aura Biosciences, Inc.", "longName": "Aura Biosciences, Inc.", "firstTradeDateEpochUtc": 1635514200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "205d4b2f-04ec-3b66-84a0-9c2c5c015d78", "messageBoardId": "finmb_100249028", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.82, "targetHighPrice": 21.0, "targetLowPrice": 19.0, "targetMeanPrice": 20.0, "targetMedianPrice": 20.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 187416000, "totalCashPerShare": 3.778, "ebitda": -89062000, "totalDebt": 19034000, "quickRatio": 17.768, "currentRatio": 18.543, "debtToEquity": 9.942, "returnOnAssets": -0.27477, "returnOnEquity": -0.4509, "freeCashflow": -47313500, "operatingCashflow": -73370000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]